Other languages Bioretec Oy

Equities

BRETEC

FI4000480454

Market Closed - Nasdaq Helsinki Other stock markets 10:47:33 2024-05-16 EDT			5-day change	1st Jan Change
2.69 ^EUR	-1.10%		-0.74%	+12.08%

04-05	Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors	CI
03-22	Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors	04-05
Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition	03-22
Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition	03-21
Bioretec Secures US FDA Breakthrough Device Designation for Spinal Interbody Cage Implant	03-14
Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage	03-14
Bioretec Expects EU Regulatory Approval for Trauma Screw in Q2	03-11
Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation	03-08
Bioretec Ltd Announces CEO Changes	11-16
Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs? Trauma Screw Will Move to the First Quarter of 2024	23-10-18
Bioretec Ltd. Enters into the U.S. Distribution Agreement with Spartan Medical Inc. for the RemeOs Screws	23-09-12
Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board	23-08-16
Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team	23-07-14
Bioretec Ltd Acquires New CNC Machining Center to Increase Production Capacity of RemeOs Products at its Factory in Tampere, Finland	23-06-13
Bioretec Oy Approves Management Appointments	23-05-26
Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor	23-05-16
Bioretec Ltd, Receives U.S. Market Authorization for Its RemeOs Trauma Screw from the U.S. Food and Drug Administration	23-04-24
Bioretec Ltd Receives Market Authorization of the U.S. Food and Drug Administration for Its Pioneering Remeos Traversed with the Clinical Trial	23-03-30
Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws	23-01-03
Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023	22-10-14
Bioretec's Hybrid Composite Patent Has Been Approved in Europe	22-09-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bioretec Oy

Equities

BRETEC

FI4000480454

Other languages

Filters